D-0789-2020 Class III Terminated

Recalled by AuroMedics Pharma LLC — East Windsor, NJ

FDA drug recall D-0789-2020 was initiated by AuroMedics Pharma LLC on Dec 2, 2019 and is designated Class III. Reason for recall: Discoloration: Market complaints of discoloration in Moxifloxacin Ophthalmic Solution. The recall status is terminated (terminated Nov 22, 2022). Affected quantity: 100,080 bottles.

Recall Details

Product Type
Drugs
Report Date
Jan 22, 2020
Initiation Date
Dec 2, 2019
Termination Date
Nov 22, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
100,080 bottles

Product Description

Moxifloxacin Ophthalmic Solution USP, 0.5%, Sterile, 3mL Bottle, Rx Only, For Topical Ophthalmic Use Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, Made in India, NDC 65862-840-03.

Reason for Recall

Discoloration: Market complaints of discoloration in Moxifloxacin Ophthalmic Solution.

Distribution Pattern

Nationwide in the U.S.

Code Information

Lot #s: CMF190008; CMF190009, Exp. 04/2021; CMF190025; CMF190026, Exp. 06/2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0789-2020
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0789-2020. Report a data issue: hello@regdatalab.com.